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Leukocyte differentiation antigens often represent important markers for the diagnosis, classification, prognosis, and
therapeutic targeting of myeloid leukemia. Herein, we report a potential leukocyte differentiation antigen gene VSTM1
(V-set and transmembrane domain-containing 1) that was downregulated in bone marrow cells from leukemia patients
and exhibited a higher degree of promoter methylation. The expression level of its predominant encoded product,
VSTM1-v1, was positively correlated with myeloid cell maturation state. Restoration of VSTM1-v1 expression inhibited
myeloid leukemia cells’ growth. Therefore, VSTM1-v1 might represent an important myeloid leukocyte differentiation
antigen and provide a potential target for the diagnosis and treatment of leukemia.
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Acute myeloid leukemia (AML) and chronic myeloid
leukemia (CML) are myeloid blood cell malignancies that
show great heterogeneity. VSTM1 (V-set and transmem-
brane domain-containing 1) encodes a potential leukocyte
differentiation antigen that is highly expressed in myeloid
cells, but silenced in multiple leukemia cell lines [1]. To
determine whether it plays a role in leukemogenesis, we
characterized its expression pattern and function in bone
marrow cells from AML/CML patients and myeloid
leukemia cell lines.
We measured VSTM1 expression in leukemia cell lines
and bone marrow biopsies from leukemia patients using
qRT-PCR. VSTM1 was downregulated or silenced in all
cell lines tested (Additional file 1: Table S1). Compared to
healthy donors (HDs), VSTM1 was downregulated in
AML (Table 1). Additionally, in CML-AP/BC (accelerated
phase/blast crisis), which clinically behaves like AML,
VSTM1 expression levels were much lower than those in
CML-CP (chronic phase, P = 0.003, Table 1). Analogous
protein expression differences were found by Western* Correspondence: ruanguorui@pkuph.edu.cn
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unless otherwise stated.blotting. Compared to HD bone marrow, VSTM1 was simi-
larly expressed in CML-CP patients, whereas it was barely
detectable in untreated AML patients. However, in AML
patients who achieved complete remission, VSTM1 expres-
sion was completely restored (Additional file 2: Figure S1).
Higher levels of VSTM1 promoter methylation in bone
marrow cells from AML patients compared to those from
HDs were observed, which might contribute to its down-
regulation (Additional file 3: Figure S2).
VSTM1-v1 is the most abundantly expressed gene prod-
uct encoded by VSTM1 [2] and is an ITIM-bearing im-
mune receptor that negatively regulates neutrophil activity
[3-5]. We used flow cytometry to divide bone marrow cells
into subpopulations based on CD45 levels and SSC [6],
and found that VSTM1-v1 was highly expressed in mature
granulocytes and monocytes from HDs (94.01 ± 6.80%
positive with a mean fluorescence intensity (MFI) of
167.61 ± 90.95), but was much less abundant in naive
cells (37.14 ± 14.47% with a MFI of 46.70 ± 23.51, n = 27;
P <0.001). Moreover, the percentage of VSTM1-v1-
positive cells among naive cells from AML patients
(19.60 ± 21.09%, n = 52, including 4 M0/M1, 22 M2, 4 M3,
14 M4, and 8 M5) was even lower than that in HDs
(P = 0.047). Therefore, we speculated that VSTM1-v1
expression might be associated with the maturity of mye-
loid cells. A combination of CD34/CD117/CD13/CD16s is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The expression level of VSTM1 in bone marrow
cells from leukemia patients and healthy donors
Groups MIC Sample size Mean ratio,
VSTM1/ABL
P valuea
HD 36 17.358 ± 17.904
Untreated AML 145 4.333 ± 7.895 <0.001
M1 3 0.374 ± 0.619 n.a.
M2 72 5.292 ± 10.171 <0.001
M3 29 2.884 ± 3.960 <0.001
M4 24 4.814 ± 5.293 0.001
M5 14 3.052 ± 4.867 <0.001
M6 3 1.417 ± 2.205 n.a.
Untreated ALL 40 0.381 ± 0.755 <0.001
Untreated CML 57 5.479 ± 8.266 <0.001
CP 38 7.743 ± 9.312 0.001
AP/BC 19 0.950 ± 1.367 <0.001
MIC morphological, immunological, and cytogenetic classifications, n.a. not
available due to a small sample size.
aThe P value was calculated using Wilcoxon signed ranks test as compared to
the HD group.
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cells was positively correlated with cell maturation state.
Differences between any two continuous stages were sig-
nificant (n = 11; P < 0.001; Table 2 and Additional file 4:
Figure S3). Using CD16 and CD14 as phenotypic markers
for mature granulocytes and monocytes, respectively, we
found a similar result (Additional file 1: Table S2). This
correlation was subsequently confirmed by increased
VSTM1 expression in bone marrow cells from APL pa-
tients and in NB4 cells after ATRA treatment in vitro
(Additional file 5: Figure S4). These findings provide a po-
tential reason why VSTM1 expression levels were reduced
so markedly in AML and CML-AP/BC patients.
Similar to its function in Jurkat cells [1], restoration of
VSTM1-v1 expression in the myeloid leukemia cell lines
K562 and MEG-01 also inhibited cell growth (Additional
file 6: Figure S5). Moreover, when searching for clinical
features that could be related to VSTM1 expression in
AML patients, we detected a higher expression level ofTable 2 The expression of VSTM1-v1 at various stages of
myelocytic differentiation














5.69 ± 2.69 11.48 ± 4.58 35.02±11.58 61.63 ± 8.53
P valuea <0.001 <0.001 <0.001
aThe P value was calculated using a Wilcoxon signed ranks test as compared
with the next stage.VSTM1 in AML1-ETO-positive patients (Additional file
1: Table S3 and Additional file 7: Figure S6). This
chimeric oncogene in AML is often associated with a
relatively favorable prognosis [7,8]. Considering the in-
hibitory effect of VSTM1-v1 on leukemia cell growth,
we can hypothesize that VSTM1-v1 might enhance the
cytotoxic effects of chemotherapeutics in patients with
this genetic abnormality.
In conclusion, our findings suggest that VSTM1-v1
might be an important myeloid leukocyte differentiation
antigen. Our elucidation of its expression pattern
throughout myeloid cell differentiation and its effect on
leukemia cell growth could help to establish it as a novel
target for the development of diagnostics and treatments
for myeloid leukemia.Additional files
Additional file 1: Table S1. The expression level of VSTM1 in leukemia
cell lines. Table S2. Correlations between VSTM1-v1 expression and
phenotypic markers of mature granulocytes and monocytes. Table S3.
Correlations between VSTM1 expression and clinical features of AML
patients.
Additional file 2: Figure S1. Western blot analysis of VSTM1 expression in
bone marrow cells. Bone marrow samples were from two healthy donors (N1
and N2), four AML patients who achieved complete remission (L1 and L2, by
bone marrow transplantation; L3 and L4, by chemotherapy), four untreated
AML patients (L5–8), and two untreated CML-CP patients (L9 and L10).
Additional file 3: Figure S2. The VSTM1 promoter was hypermethylated
in AML patients. (A) Methylation-specific PCR (MSP) of the VSTM1 promoter
in bone marrow samples from eight AML patients (lanes 1–8). Among them,
seven samples (lanes 1–3, and 5–8) were partially methylated and one (lane
4) was completely methylated; M, methylated; U, unmethylated. (B) Bisulfite
genomic sequencing (BGS) of the VSTM1 promoter in bone marrow samples
from four healthy donors and four AML patients were carried out, which
demonstrated that VSTM1 underwent increased promoter methylation in
AML patients (57/208, 27.40%) compared to healthy donors (18/208, 8.65%;
P < 0.05). Representative results from a healthy donor (HD) and an AML patient
are shown. Circles, CpG sites that were analyzed; rows of circles, an individual
promoter allele that was cloned, randomly selected, and sequenced; filled circle,
a methylated CpG site; open circle, an unmethylated CpG site.
Additional file 4: Figure S3. Flow cytometric analysis of VSTM1-v1
expression in subpopulations of bone marrow cells from healthy donors. A
representative result is shown. (A) CD45 intensity and side scatter (SSC) were
used to set gates for lymphocytes (CD45high SSClow), mature granulocytes
(CD45int SSChigh), monocytes (CD45high SSCint) and naive cells (CD45int
SSClow). The percentages of VSTM1-v1-positive cells in each population were
determined. (B) The naive cell population in (A) was then further gated
based on combinations of CD34, CD117, CD13, and CD16 staining and were
classified into myeloblasts (CD34+), promyelocytes (CD34−CD117+CD16−),
myelocytes (CD34−CD117−CD16−CD13+) and metamyelocytes (CD16+). The
percentages of VSTM1-v1-positive cells in each population were determined.
Additional file 5: Figure S4. VSTM1-v1 expression was restored in APL
cells by ATRA treatment. (A) qRT-PCR for VSTM1 expression in bone marrow
cells from two APL patients that were untreated or treated with ATRA for 7 days
in vitro. (B) Flow cytometric analysis of the percentage of VSTM1-v1-positive NB4
cells that were untreated or treated with ATRA for 5 days. CD11b expression
was measured as a marker of differentiation. A representative result of three
independent experiments is shown. (C) The correlation of the MFI of
VSTM1-v1 and CD11b at various time points following treatments with different
concentrations of ATRA was evaluated by Pearson’s correlation analysis
(n = 17; r = 0.866; P < 0.001).
Xie et al. Journal of Hematology & Oncology  (2015) 8:25 Page 3 of 3Additional file 6: Figure S5. Overexpression of VSTM1-v1 inhibited
K562 and MEG-01 cell growth. (A) Overexpressed VSTM1-v1 was detected
on the cell surface by flow cytometry. Cell growth curves of K562 (B) and
MEG-01 (C) cells were generated based on viable cell counting assays
after VSTM1-v1 transfection. Error bars represent SD; *, P < 0.05, compared
to the vector control at each time point. Representative results of at least
three independent experiments are shown.
Additional file 7: Figure S6. Correlations between VSTM1 expression in
AML patients and gender or the AML1-ETO fusion gene. (A) The expression
level of VSTM1 was higher in male than in female patients (median, 2.45
[0.00–171.90] vs. 1.03 [0.00–19.03]; P = 0.010). (B) The expression level of
VSTM1 was higher in AML1-ETO-positive (n = 46) than in AML1-ETO-negative
(n = 44) patients (median, 2.58 [0.00–44.62] vs. 0.74 [0.00–54.08]; P < 0.001).
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